These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7805040)

  • 1. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression.
    Harpole DH; Herndon JE; Wolfe WG; Iglehart JD; Marks JR
    Cancer Res; 1995 Jan; 55(1):51-6. PubMed ID: 7805040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients.
    Harpole DH; Marks JR; Richards WG; Herndon JE; Sugarbaker DJ
    Clin Cancer Res; 1995 Jun; 1(6):659-64. PubMed ID: 9816029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prognostic value of expression of FASE, HER-2/neu, bcl-2 and p53 in stage I non-small cell lung cancer].
    Wang Y; Zhang XR; Fu J; Tan W; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):369-72. PubMed ID: 15312350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
    Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small-cell lung cancer.
    Yu CJ; Shun CT; Yang PC; Lee YC; Shew JY; Kuo SH; Luh KT
    Am J Respir Crit Care Med; 1997 Apr; 155(4):1419-27. PubMed ID: 9105088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis.
    Dosaka-Akita H; Hu SX; Fujino M; Harada M; Kinoshita I; Xu HJ; Kuzumaki N; Kawakami Y; Benedict WF
    Cancer; 1997 Apr; 79(7):1329-37. PubMed ID: 9083154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer.
    Giatromanolaki A; Koukourakis MI; Kakolyris S; Turley H; O'Byrne K; Scott PA; Pezzella F; Georgoulias V; Harris AL; Gatter KC
    Clin Cancer Res; 1998 Dec; 4(12):3017-24. PubMed ID: 9865915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
    Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
    Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival after pathological stage IA nonsmall cell lung cancer: tumor size matters.
    Birim O; Kappetein AP; Takkenberg JJ; van Klaveren RJ; Bogers AJ
    Ann Thorac Surg; 2005 Apr; 79(4):1137-41. PubMed ID: 15797040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
    Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
    Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
    Suthipintawong C; Wejaranayang C; Vipupinyo C
    J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in resected stage I non-small cell lung cancer with a diameter of 3 cm or less: visceral pleural invasion did not influence overall and disease-free survival.
    Hung JJ; Wang CY; Huang MH; Huang BS; Hsu WH; Wu YC
    J Thorac Cardiovasc Surg; 2007 Sep; 134(3):638-43. PubMed ID: 17723811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
    Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
    Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer.
    Harpole DH; Richards WG; Herndon JE; Sugarbaker DJ
    Ann Thorac Surg; 1996 May; 61(5):1470-6. PubMed ID: 8633961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Retinoid expression (RARbeta and CRBP1) in non-small-cell lung carcinoma].
    Mauro LV; Dalurzo M; Smith D; Lastiri J; Vasallo B; Joffei EB; Pallotta MG; Puricelli L
    Medicina (B Aires); 2008; 68(3):205-12. PubMed ID: 18689151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
    Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study of prognostic factors in patients with stage I non-small cell lung cancer].
    Jiang ZQ; Jiang GL; Shi DR; Zhang RX; Fu XL; Qian H
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):364-8. PubMed ID: 15312349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas.
    Yi ES; Harclerode D; Gondo M; Stephenson M; Brown RW; Younes M; Cagle PT
    Mod Pathol; 1997 Feb; 10(2):142-8. PubMed ID: 9127320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
    Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
    Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.